[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502451":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":29,"collaborators":7,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":35,"acronym":7,"eligibilityCriteria":36,"healthyVolunteers":33,"sex":37,"minAge":38,"maxAge":7,"enrollmentInfo":39,"targetDuration":7,"studyType":42,"phases":7,"briefSummary":43,"conditions":44,"keywords":46,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":58},{"fullName":5,"class":6},"Imugene Limited","INDUSTRY",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Clinical Imugene Limited","CONTACT","1 984 245 0082","info@imugene.com",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":7},"Science 37, Inc.","RECRUITING","Culver City","California","90230","United States","US",{"type":24,"coordinates":25},"Point",[26,27],-118.39647,34.02112,{"lat":27,"lon":26},{"type":30,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100502451","long-term-follow-up-of-study-participants-who-received-an-allogeneic-chimeric-antigen-receptor-t-cell-product-in-an-imugene-ltd-clinical-study-100502451",false,"NCT05822427","Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study","Inclusion Criteria:\n\n* Receipt of at least 1 dose of azer-cel in an Imugene clinical study.\n* A signed informed consent form (ICF).\n* Willingness and ability to adhere to the study schedule and all other protocol requirements.\n\nExclusion Criteria:\n\n* No unique exclusion criteria apply to this study.","ALL","18 Years",{"count":40,"type":41},75,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to collect information on the long-term safety of study participants who received an Allogeneic Chimeric Antigen Receptor (CAR) T-Cell Product in an Imugene Clinical Study. The main questions it aims to answer are:\n\n* What are the frequency, severity, duration, and outcome of clinically significant Clinical Events of Interest (CEI)?\n* What is the duration of response and overall survival time after taking an allogeneic CAR T-Cell product on an Imugene clinical study?\n\nParticipants will have a yearly visit either face to face or remotely for up to 15 years to check for CEI.",[45],"Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical Study",[47,48],"Allogeneic chimeric antigen receptor (CAR) T cell products","azer-cel","2025-05-11",{"date":51,"type":52},"2025-05-14","ACTUAL",{"date":54,"type":52},"2020-08-25",{"date":56,"type":41},"2039-12",{"name":5,"class":6},1]